Strong Initial Efficacy Data Reported in 3L NSCLC from Ph 2 THIO-101 Part C Expansion Trial July 15, 2026
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development July 15, 2026
Jemperli achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer July 15, 2026
FDA Accepts NDA for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma; PDUFA: May 2027 July 15, 2026
FORE Biotherapeutics Announces Closing of Upsized $67.4 Million Series D-2 Extension Financing and Highlights Recent Plixorafenib Achievements July 15, 2026
Global Ph 3 study of HBI-8000 plus nivolumab met the PFS primary endpoint in frontline patients with advanced melanoma July 15, 2026
FDA approves SC Sarclisa (isatuximab-irfc) Escena + SOC for multiple myeloma patients across all existing indications of Sarclisa IV formulation July 15, 2026
Allotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell Cancers July 15, 2026
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer July 15, 2026
AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical July 15, 2026
FDA Registration-Enabling Ph 3 Confirmatory Study of Multikine® launched in Newly Diagnosed Head and Neck Cancer July 15, 2026
Publication in The JCO Demonstrating DeltEx DRI Doubles PFS in Newly Diagnosed Glioblastoma July 15, 2026
Results from ELEVATE study of postoperative adjuvant ensartinib in stage IB–IIIB (T3N2M0) ALK-positive NSCLC published in NEJM July 15, 2026
Updated Preliminary Ph 1 Data and Registration-Enabling Plans for ERAS-0015 in KRAS-Mutant Solid Tumors Announced July 15, 2026
Primary Results Announced from Ph 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs July 15, 2026
Updated Survival Data Presented from Ph 3 Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses July 15, 2026
Clinical results of Ph 1b/2 trial of ifebemtinib + garsorasib in 1L KRASG12C-mutant NSCLC published in The Lancet Respiratory Medicine July 15, 2026
Global Data for Pumitamig Shows Encouraging Efficacy in NSCLC Patients in ROSETTA Lung-02 Trial July 15, 2026
Orphan Drug Designation Request submitted to the FDA for GDT Cell Therapy Targeting Glioblastoma July 15, 2026
ESMO GI 2026: BOT+BAL Data Showing 33% Three-Year OS in Refractory MSS Metastatic CRC Without Active Liver Metastases July 15, 2026
FDA sends CRL for Combination of Rivoceranib and Camrelizumab as 1L Treatment for Unresectable or Metastatic HCC July 15, 2026
